Dmitry Balyasny’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Dmitry Balyasny’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,374,100	Closed	-$159M	–	3047
2023 Q3	$159M	Sell	1,374,100 -16,300	-1%	-$1.75M	0.32%	47
2023 Q2	$143M	Buy	1,390,400 +163,800	+13%	+$17.3M	0.31%	52
2023 Q1	$134M	Sell	1,226,600 -245,200	-17%	-$27.1M	0.34%	42
2022 Q4	$167M	Buy	1,471,800 +1,467,800	+36,695%	+$122M	0.46%	20
2022 Q3	$248K	Buy	+4,000	New	+$279K	﹤0.01%	2256
2019 Q3	–	Sell	-200,000	Closed	-$4.75M	–	1795
2019 Q2	$4.75M	Buy	+200,000	New	+$5.07M	0.03%	619
2015 Q2	–	Sell	-200,000	Closed	-$5.19M	–	1426
2015 Q1	$5.19M	Sell	200,000 -170,000	-46%	-$3.12M	0.04%	471
2014 Q4	$4.77M	Buy	+370,000	New	+$4.63M	0.04%	444

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Dmitry Balyasny's HZNP Position: Q4 2023 in Review

Dmitry Balyasny sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,212,745 shares — an estimated $256M sold.

Dmitry Balyasny first reported a position in HZNP in Q1 2016 and held it in 24 quarters. The position peaked at $256M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Dmitry Balyasny reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Dmitry Balyasny sold 2,212,745 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $256M.
Dmitry Balyasny first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 24 quarters.
Dmitry Balyasny's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $256M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.